Viewing Opinion | StockChase
Becton Dickinson (BDX-N) opinion on 2017-05-19

Last Price Recorded: 220.3100 on 2017-11-17

ON STOCKCHASE SINCE May 2003

biotechnology/pharmaceutical
TOP PICK

David Driscoll
Becton Dickinson was $184.130 at time of opinion
Owned : Yes

This started a long time ago making syringes and needles, and that’s pretty much been their core. It’s all consumables in the hospitals, etc. Just made a recent acquisition of CR Bard (BCR-N) in the urology business. Both companies generate consistently growing free cash flows. There’s a 10% bump to the dividend every year. This merger is going to give them some debt that should be paid off within the next 2 years. He likes the company at this price.

UNKNOWN

All opinions for BDX-N (30)

9 BUY
1 BUY on WEAKNESS
1 COMMENT
2 HOLD
5 PAST TOP PICK
12 TOP PICK
View All

More experts covering BDX-N

SAVE
Add BDX-N to Watch List

All opinions for BDX-N (30)

9 BUY
1 BUY on WEAKNESS
1 COMMENT
2 HOLD
5 PAST TOP PICK
12 TOP PICK
View All

More experts covering BDX-N

SAVE
Add BDX-N to Watch List

No Comments.


You must be logged in to comment.

Successfully Saved Company